Neurobiological Technologies Overview
- Founded
- 1987
- Status
- Public
- Employees
- 6
- Stock Symbol
- NTII
Neurobiological Technologies General Information
Description
Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.
Contact Information
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Stock Exchange
PINX
Primary Office
- 2010 Crow Canyon Place
- Suite 100
- San Ramon, CA 94583
- United States
+1 (925) 000-0000
Neurobiological Technologies Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 7.16K |
Neurobiological Technologies Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2009 | FY 2009 30-Jun-2009 | FY 2008 30-Jun-2008 | FY 2007 30-Jun-2007 |
|---|---|---|---|---|
| EV | (2,005) | (5,624) | 9,829 | 53,478 |
| Revenue | 28,811 | 26,350 | 14,760 | 17,673 |
| EBITDA | 8,721 | 2,507 | (13,898) | |
| Net Income | 11,290 | 3,123 | (16,322) | (14,128) |
| Total Assets | 29,782 | 24,660 | 43,187 | 10,921 |
| Total Debt | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Neurobiological Technologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Neurobiological Technologies‘s full profile, request access.
Request a free trialNeurobiological Technologies Patents
Neurobiological Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20040224006-A1 | Defibrinogenating agent, e.g., ancrod, urokinase, streptokinase, phenobarbital or valproic acid; or a fibrinolytic agent, e.g., advance-generation fibrates, e.g., fenofibrate, a tissue-plasminogen activator that may be recombinant, or a fibrinolytic derivative of recombinant tissue-plasminogen activator | Abandoned | 21-Apr-2003 | 0000000000 | 0 |
| AU-6104196-A | Novel n-substituted-2-amino-3',4'-methylene-dioxypropiopheno nes | Abandoned | 06-Jun-1995 | 0000000000 | |
| CA-2175457-A1 | Treatment for rheumatoid arthritis | Abandoned | 02-Nov-1993 | 00000000000 | |
| AU-8131694-A | Treatment for rheumatoid arthritis | Abandoned | 02-Nov-1993 | 00000000000 | |
| EP-0726780-A1 | Treatment for rheumatoid arthritis | Withdrawn | 02-Nov-1993 | A61K38/2228 |
Neurobiological Technologies Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| William Fletcher | Chief Executive Officer & Board Member | ||
| Matthew Loar | Chief Financial Officer, Finance & Board Member | ||
| John Stuppin | Co-Founder |
Neurobiological Technologies Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000000 00000 | Self | Chairman & Board Member | 000 0000 |
| 0000000 000000 | Neurobiological Technologies | Board Member | 000 0000 |
| 0000 0000000 | Neurobiological Technologies | Co-Founder | 000 0000 |
| 0000000 0000 | Neurobiological Technologies | Chief Financial Officer, Finance & Board Member | 000 0000 |
| 00000000 00000 | Neurobiological Technologies | Board Member | 000 0000 |
Neurobiological Technologies Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial